The E-selectin cell adhesion protein plays a critical role in mediating adherence of leukocytes to endothelium at sites of inflammation. Cytokine-induced E-selectin expression on the surface of endothelial cells is transient; mRNA expression peaks at 3-4 h after induction and returns to basal levels within 24 h. The mechanism for this transcriptional down-modulation is not known. Promoter binding factors responsible for induced gene expression include NF-κB, which binds at three sites within the E-selectin promoter, and HMG-I(Y), which binds to the A/T-rich core found at the centre of these binding sites. Distamycin is an antibiotic that also binds A/T-rich DNA and inhibits HMG-I(Y) DNA binding. To study the role of HMG-I(Y) in E-selectin expression, we have examined the effect of distamycin on the cytokineinduced E-selectin expression cycle. We found that distamycin prolonged E-selectin expression, both by sustaining mRNA transcription and by extending the transcript's half-life. The distamycin effect on transcription was mediated through one of the three NF-κB-HMG-I(Y) binding sites (NF-κBII) within the promoter. This suggests that the NF-κB-HMG-I(Y) complex interacting at the NF-κBII site plays a role not only in cytokine induction of E-selectin expression, but also in its down-modulation.
INTRODUCTION
E-Selectin (also known as CD62E and ELAM-1) is a membrane glycoprotein exclusively expressed on the surface of endothelial cells during inflammation in vivo or after cytokine, lipopolysaccharide or phorbol ester induction in vitro (1) (2) (3) (4) (5) . E-Selectin plays a critical role at inflammation sites in mediating the adhesion to endothelial cells and extravasation of neutrophils and a subset of T lymphocytes. Both up-and down-modulation of this selectin is tightly controlled. Several transcription factors and their cognate DNA binding elements in the E-selectin promoter have been identified that are essential for activation of the E-selectin promoter. NF-κB binding to the -94/-85 region in the E-selectin promoter is essential but not sufficient for cytokine induction of the gene (6) (7) (8) (9) . Induction of the E-selectin promoter also requires NF-κB complexes to bind at positions -126 (10, 11) and -116 (10, 12) . Moreover, E-selectin promoter activation requires members of the ATF family of transcription factors that bind the NF-ELAM1 site at position -157 (13, 14) and as yet unidentified protein(s) binding the NF-ELAM-2 site at position -104 (13) . Tissue specificity of the E-selectin gene is associated with CpG methylation of the proximal promoter (15) .
Binding of NF-κB and ATF factors to their promoter sites is enhanced by a member of the high mobility group family of proteins, HMG-I(Y) (11) (12) (13) (14) . High mobility group proteins are non-histone chromosomal proteins that have been shown to bind the minor groove of A/T-rich regions of double-stranded DNA in vitro (16) . HMG-I(Y) also plays an important role in virusmediated induction of the β-IFN gene through its interaction with NF-κB (17, 18) .
Several compounds (e.g. distamycin, berenil, bis-benzamidine and netropsin) have been described that compete with HMG-I(Y) for binding in the minor groove of A/T-rich DNA regions (19) (20) (21) . As HMG-I(Y) binds to the E-selectin promoter and plays a role in its activation, we decided to analyse the effect of these specific competitors of HMG-I(Y) binding on activation of the E-selectin promoter by cytokine treatment of endothelial cells. In contrast to our expectation of reduced or blocked E-selectin expression, we found that distamycin significantly prolonged E-selectin expression induced by both IL-1β and TNF-α. We have studied the mechanism of this distamycin effect to learn more about the role of HMG-I(Y) in the regulation of E-selectin transcription. We show that the NF-κBII element in the E-selectin promoter is responsible for the distamycin effect and is likely to play a role in the physiological down-modulation of E-selectin gene expression, possibly through DNA-bending.
MATERIALS AND METHODS

Cell culture
Human endothelial cells (HUVECs) were isolated from human umbilical cords by collagenase treatment and grown as previously * To whom correspondence should be addressed. Tel: +41 22 706 97 38; Fax: +41 22 794 69 65; Email: pfg8091@ggr.co.uk described (22) . All experiments were performed using HUVECs at passages 3-5.
Flow cytometry determination of E-selectin, VCAM-1 and ICAM-1
HUVECs were grown to confluence in 5 cm Petri dishes, pre-treated for different times with distamycin (10 µM) and induced for 4 h with 10 U/ml IL-1 in complete Clonetics medium containing 2% foetal calf serum. Cells were removed with the help of a rubber policeman in phosphate-buffered saline (PBS), 1 mM EDTA pre-warmed at 37_C. Cells were collected by spinning for 5 min at 1000 r.p.m. at 4_C and re-suspended in PBS containing 10 mg/ml BSA and 0.1 mg/ml NaN 3 . Cells (4 × 10 5 ) were incubated for 30 min at 4_C in the presence of the first monoclonal antibody, washed and incubated for a further 15 min at 4_C in the presence of a second antibody (anti-mouse-IgG conjugated to FITC). The cells were washed in PBS, BSA and submitted to FACS analysis. The MFI values from three different experiments are expressed as a percentage of the maximal value obtained with 10 U/ml IL-1.
Preparation of RNA and Northern blot analysis
Total RNA was isolated from confluent HUVECs using the guanidinium isothiocyanate/CsCl procedure (23) . Total RNA (20 µg/lane) was fractionated on a 1% agarose gel containing 2.2 M formaldehyde, blotted onto nylon membrane filters (GeneScreen Plus; NEN) and hybridized to nick-translated E-selectin-1, ICAM-1, VCAM-1 or human β-actin 32 P-labelled cDNA probes (24) . Filters were washed twice for 30 min at 37_C in 2× SSC, 0.1% SDS and for 15 min at 55_C in 0.2× SSC, 0.1% SDS and then exposed for different times to Kodak XAR films at -80_C. Results were visualized by autoradiography and quantified using an Ambis (San Diego, CA) radioactivity scanner.
Nuclear run-on transcription assays
HUVECs which had been left untreated or pre-treated for 24 h with distamycin (10 µM) were incubated with human IL-1β (10 U/ml) in the presence or absence of distamycin (10 µM) and nuclei were isolated after 1, 6 or 24 h. Nuclear run-on assays were performed as previously described (22) starting with 3 × 10 7 cells/treatment. For each assay, nuclei were re-suspended in 300 µl transcription buffer containing 250 µCi [α-32 P]UTP and incubated for 20 min at 30_C. The radiolabelled RNA was purified using the guanidinium isothiocyanate/CsCl procedure (23) and equal amounts of c.p.m. were used for hybridization to nitrocellulose filters that contained alkali-denatured target cDNA. The filters were prepared by slot blotting of 7.5 µg target DNA followed by baking for 2 h in vacuo at 80_C. The DNAs used were plasmids pCDM8 and pELAM-1 (plasmid pCDM8 containing E-selectin cDNA; 22). Results were visualized by autoradiography and quantified by densitometric scanning of the autoradiograms.
Plasmid constructs
The plasmid constructs were made by inserting different E-selectin promoter regions into the EcoRI site of a pCAT-promoter plasmid (Promega) containing the enhancerless SV40 promoter. The plasmid used (as shown in Fig. 7) contained; (i) the -383 promoter region with the NF-κBI and NF-κBII wild-type elements; (ii) the NF-κBI wild-type element and a mutated NF-κBII element; (iii) a mutated NF-κBI and a NF-κBII wild-type element, as described earlier (14) .
DNA transfection and CAT analysis
Transfection of plasmid DNA into HUVECs was carried out using the DEAE-Dextran method as described (25) . HUVECs were pre-treated for 24 h with distamycin, transfected and treated with distamycin alone or in combination with IL-1β (40 U/ml). After 24 h treatment, the cells were collected by scraping and cellular extracts were used for chloramphenicol acetyl transferase (CAT) assays essentially as described (26) . CAT enzymatic activity was quantified using an Ambis (San Diego, CA) radioactivity scanner.
DNase I footprinting
For DNase I footprinting a PCR-generated DNA fragment that spanned part of the E-selectin promoter (-162 to -71) and contained the three NF-κB sites was used: GTA ACA CAG AGT TTC TGA CAT CAT TGT AAT TTT AAG CAT CGT GGA TAT TCC CGG GAA AGT TTT TGG ATG CCA TTG GGG ATT TCC TCT TTA CTG GAT GTG GAA CC. The 5′ primer was 5′-end-labelled with [γ-32 P]ATP prior to the PCR reaction (27) . The template utilized for PCR was a basic pCAT-Promega vector containing the -383 region of the E-selectin promoter.
The in vitro DNase I assay protocol was performed by incubating this fragment for 10 min at room temperature with 1.5 U/ml DNase I, after pre-incubation for 1 h on ice in the absence or presence of distamycin at various concentrations. Digested products were analysed on 8% polyacrylamide (19:1 acrylamide/ bis-acrylamide), 50% urea, 0.5× TBE sequencing gels.
DNA bending analysis
Subcloning of the NF-κBI element into pBEND2 was described previously (28) . In order to insert the NF-κBII element, oligonucleotides CTA GCC CGG GAA TAT CCA CGA TG and TCG ACA TCG TGG ATA TTC CCG GG were phosphorylated, annealed and cloned into the XbaI-SalI sites of pBEND2 using standard procedures (29) . PBEND2 (30) was a kind gift of Dr S.Adhya. The resulting construct was sequenced to verify that it contained a single insert. The polylinkers plus insert from both constructs were PCR amplified using oligonucleotides PCRBEND2a and PCR-BEND2b (28) . The resulting fragments were treated with phenol, cut separately with the different restriction enzymes, treated with phosphatase, purified from a MetaPhor agarose (FMC BioProducts) gel, end-labelled using [γ-32 P]ATP and purified again on a 12% non-denaturing polyacrylamide gel. The total length of each of the probes was 139 bp. The probes were incubated for 20 min on ice in 25 µl BCA buffer (13, 27, 31 ) and 3 µg poly(dI·dC) (Pharmacia) with or without 0.1 mM distamycin. Migration was at room temperature in a 6.5% acrylamide, 0.5× TBE gel (1.5 mm thick, 16 × 18 cm; Hoefer Scientific). The gel was run at 10 mA for 1.5 times the time taken for the bromophenol blue marker to run off the gel. 
RESULTS
Distamycin prolongs cytokine-induced E-selectin expression in endothelial cells
E-Selectin expression on the surface of endothelial cells peaks 4-5 h after cytokine induction and both protein and mRNA return to their basal levels within 24 h. This drop in E-selectin mRNA transcription occurs even in the continuous presence of cytokine ( Fig. 1A; 1,6 ) and even though high levels of NF-κB persist up to 48 h post-induction (32) . To study the role of HMG-I(Y) in this cytokine-induced, transient E-selectin expression, we treated HUVECs with IL-1 in conjunction with distamycin. Since distamycin is capable of inhibiting HMG-I(Y) binding to DNA (19) , we anticipated an inhibition of E-selectin expression. In contrast, we observed that when E-selectin expression was induced by IL-1 in the presence of distamycin, the high level of E-selectin protein measured by flow cytometry (FACS) was significantly prolonged (Fig. 1A) . At 24 h post-IL-1 induction, distamycin maintained E-selectin expression at ∼70-80% of the maximal level observed at 4 h post-induction. At 96 h, the level of E-selectin expression in IL-1 plus distamycin-treated cells had only fallen to ∼50% of the maximum level.
The prolongation of E-selectin protein expression in the presence of distamycin is reflected in a similar persistence of E-selectin mRNA, as measured by Northern blot analysis (Fig. 2) .
The level of E-selectin mRNA 24 and 48 h after the onset of IL-1 induction and in the presence of distamycin was close to that observed at 3 or 6 h following IL-1 induction alone ( Fig. 2A , lanes 11 and 13 versus 2 and 4, and Fig. 2B ). To test if the continuous presence of distamycin is required for sustained E-selectin expression, we removed the compound 24 h after induction with IL-1 plus distamycin. Removal of distamycin by rinsing the cells resulted in a decrease in E-selectin mRNA accumulation during the following 24 h (Fig. 3, lane 6) . We found that distamycin did not increase the peak level of E-selectin expression induced after 4 h IL-1 treatment (Figs 1A and 2A) . Moreover, distamycin alone induced neither E-selectin protein nor mRNA expression ( Figs  1A and 2A) . Cell viability was not affected by distamycin treatment as measured in a proliferation assay (data not shown). Taken together, our results suggest that distamycin is capable of inhibiting the down-regulation of E-selectin expression.
To determine whether the distamycin-induced prolongation of E-selectin expression is specific or is also observed with other compounds that bind A/T-rich regions of DNA, we also tested the effect of bis-benzimide, berenil and netropsin on E-selectin expression following IL-1 induction. Unlike distamycin, these compounds did not affect IL-1-induced E-selectin mRNA or protein expression as determined by Northern blot (Fig. 4) or FACS analysis (data not shown). Thus, distamycin appears to differ in its activity on the E-selectin promoter from other compounds that bind A/T-rich regions of DNA.
To analyse whether the maintenance of expression by distamycin is specific to E-selectin, we examined the effect of distamycin on another adhesion protein, VCAM-1. Like E-selectin, VCAM-1 is transiently expressed on endothelial cells following cytokine induction. The expression of VCAM-1 is maximal 6-8 h following IL-1 induction (33-36). We did not observe strongly increased VCAM-1 expression on distamycin treatment as observed by FACS (Fig. 1B) or by Northern blot analysis (Fig.  2) , similarly to distamycin's lack of effect on actin. These results suggest that the effect of distamycin in prolonging E-selectin gene expression is specific and not a general effect on transcription of proteins transiently expressed by endothelial cells.
Distamycin's mode of action involves both enhanced E-selectin gene transcription and increased E-selectin mRNA stability
We wished to evaluate whether an enhanced transcription initiation rate or increased mRNA stability are part of the mechanism by which distamycin prolongs E-selectin expression. To examine mRNA stability we measured the E-selectin mRNA half-life in the presence and absence of distamycin following IL-1 treatment. The transcript's half-life was determined by monitoring the level of E-selectin mRNA at different times following treatment of cells with actinomycin D, an inhibitor of ongoing transcription. A stabilization of E-selectin mRNA was seen when cells were induced by cytokine in the presence of distamycin (Fig.  5A ). To determine a distamycin effect on the rate of E-selectin gene transcription, we performed transcriptional run-on analysis. In nuclei purified from IL-1-induced endothelial cells pre-treated with distamycin, ongoing E-selectin transcription was assayed at different times following IL-1 induction. Transcription of the E-selectin gene was maintained longer following distamycin treatment ( Fig. 5B and C, lanes 4, 6 and 8 versus 3, 5 and 7) . We conclude that the prolonged E-selectin expression caused by distamycin results both from mRNA stabilization and prolonged E-selectin transcription.
Distamycin binds the E-selectin promoter NF-κBII site
To analyse the region(s) in the E-selectin promoter to which distamycin binds, we performed in vitro DNase I footprinting. We used a fragment containing the region of the E-selectin promoter previously defined as being sufficient to mediate cytokine induction (positions -162 to -71). In the presence of distamycin, the region corresponding to the NF-κBII site (-117 to -108) was protected (Fig. 6) . In contrast, neither the NF-κBI (-84 to -860) nor the NF-κBIII (-117 to -118) site was strongly protected in the presence of distamycin. These results suggest that the effect of 3) or with IL-1 plus distamycin (lanes 5 and 6), berenil (lanes 8 and 9), bis-benzamidine (lanes 11 and 12) or netropsin (lanes 14 and 15). All these compounds were used at 10 µM final concentration. RNA was blotted and hybridized to E-selectin and actin probes. Prokaryotic and eukaryotic rRNAs were used as size markers.
distamycin on E-selectin gene expression is specifically mediated through the NF-κBII site.
Distamycin acts through the proximal E-selectin promoter elements
We also attempted to narrow down the E-selectin promoter element(s) involved in distamycin's up-regulation in a functional assay. E-Selectin promoter-CAT reporter constructs in which specific NF-κB sites had been mutated were tested in transient transfection assays. As found previously (6), the 383 bp proximal E-selectin promoter sequence was sufficient to mediate IL-1 induction of a fused reporter gene (Fig. 7A) . Using the same construct, we also found that induction was greatly enhanced when cells had been treated with IL-1 in the presence of distamycin (Fig. 7A) . In this assay system, distamycin alone was only able to weakly activate the E-selectin promoter. Thus, the distamycin effect on endothelial cell expression of E-selectin is mediated by a restricted region of the E-selectin promoter. When the NF-κBI site was mutated, IL-1 induced very weak expression of the E-selectin promoter and distamycin significantly enhanced this IL-1 induction (Fig. 7B) . This result suggests that the distamycin effect is not mediated by the NF-κBI site. Finally, a mutation in the NF-κBII site resulted in a near complete loss of IL-1 induction (Fig. 7C) and in a complete loss of any distamycin effect. These data indicate that the NF-κBII site plays a critical role in E-selectin mRNA transcription; in contrast to the NF-κBI site, its loss cannot be functionally compensated for by addition of distamycin. These findings are consistent with the role we propose for NF-κBII as the site of distamycin action. 
Distamycin alters the geometry of the NF-κBII site
A possible mode of action for distamycin could be the displacement of a transcriptional repressor or to increase the binding of a trans-activator to the E-selectin promoter. However, band shift experiments with radiolabelled oligonucleotides carrying NF-κBI or NF-κBII sites and nuclear extracts prepared from cells treated with interleukin or interleukin plus distamycin failed to show a difference in protein binding (data not shown). We therefore hypothesize that distamycin has a subtler effect on the E-selectin promoter. Many HMG-like proteins are known to bend the DNA to which they bind (37, 38) , whereas binding of distamycin results in a 'straightening out' or 'unbending' of DNA (39) (40) (41) . We have previously shown that several transcription factors known to activate the E-selectin promoter also induce DNA bending when bound to their E-selectin promoter sites. Moreover, we have shown that intrinsically bent DNA sequences can functionally replace factor binding to some of the crucial elements that activate the E-selectin promoter (28) . A possibility for distamycin's mode of action is that it alters the geometry of the E-selectin promoter. We therefore examined how distamycin affects bending of the E-selectin NF-κBI and NF-κBII sites by use of a technique called phasing analysis (30) . For this assay, the NF-κB-containing DNA elements were cloned into a plasmid between two direct repeats carrying multiple restriction sites (Fig.  8A) . The elements were excised from the vector using one of the 
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set of restriction enzymes that cut in the repeats. The fragments were radioactively labelled, incubated with distamycin and migrated in a polyacrylamide gel. As all fragments have near identical molecular weights and electrostatic charge, altered migration patterns are indicative of differences in conformation. The results in Figure 8B show migration of the NF-κBI and NF-κBII DNA fragments incubated in the presence or absence of distamycin. As judged by its migration, insertion of the NF-κBII element resulted in a high degree of distortion of the DNA, but addition of distamycin caused all fragments to run with the same mobility (Fig. 8B, right panel) . In contrast, the NF-κBI element caused considerably less distortion (Fig. 8B, left panels) , both in the absence and presence of distamycin.
We conclude that the NF-κBII site is subject to a significant conformation change when bound by distamycin, unlike the relatively constant NF-κBI site.
DISCUSSION
We have recently shown (11) that HMG-I(Y) is involved in the regulation of E-selectin gene expression by enhancing NF-κB binding to three regions in the proximal promoter. From the known properties of distamycin to bind the minor groove of A/T-rich DNA regions and to block HMG-I(Y) binding to DNA, we hypothesized that this compound would inhibit the induction of E-selectin expression. Contrary to our expectation, distamycin significantly extended the duration of maximal E-selectin expression. We show here that distamycin treatment both prolongs the duration of E-selectin transcription and stabilizes E-selectin mRNA. The stabilization of E-selectin mRNA by distamycin is puzzling, since distamycin is not known to bind RNA. A possibility is that an E-selectin mRNA degradation pathway exists that itself depends on transcription and translation.
More evidence for such a pathway comes from our earlier finding (22) that the protein synthesis inhibitor cycloheximide also increases the E-selectin mRNA half-life. It would be of interest to investigate distamycin's effect on other unstable mRNAs.
Our run-on results support distamycin extending E-selectin maximal expression by acting through the protein complex binding at the NF-κBII element on the promoter. The three findings consistent with this mechanism are: (i) DNase I protection footprinting carried out in the presence of distamycin shows that only the NF-κBII (-126) site is protected from DNase digestion; (ii) mutation of NF-κB sites shows that NF-κBI is dispensable for a functional distamycin response, whereas deletion of the NF-κBII site results in no response at all; (iii) distamycin reduces bending on the NF-κBII site, but not the NF-κBI site.
Our results suggest that distamycin treatment mediates its effect predominantly (or only) through one site (NF-κBII) of the E-selectin promoter. This observation suggests that the complex that binds site II has a distinct role from those binding the other two sites, possibly because of a different protein composition (11, 32) . Furthermore, the sequence of the NF-κBII site, unlike the NF-κBI site, differs from the canonical NF-κB binding sequence consensus (42, 43) . The fact that the NF-κBII element, unlike the NF-κBI site, is completely conserved between mouse and man (44) is another indication of a special role for this element. It was found recently that binding of different NF-κB complexes is determined by the precise sequence of the NF-κB binding site within the promoter (45) . The sequence of the NF-κBII site differs from the consensus sequence at the seventh nucleotide, where an adenine instead of a pyrimidine residue (consensus sequence) is found (45) . This sequence difference may allow a different NF-κB complex to bind the site, explaining the preferential binding of distamycin and the subsequent effect on E-selectin expression.
HMG-I(Y) has been described as a specific co-activator of NF-κB (45) . Our results may be explained by a dual role of the complex that binds the NF-κBII site of the E-selectin promoter. A number of examples exist where NF-κB binding sites play a role in the repression of gene expression (46) (47) (48) (49) . In one example Dorsal, a Drosophila rel-family protein, not only activates but also represses transcription (50) . Recently, a Drosophila HMG1-like protein (DSP-1) has been identified that converts Dorsal and NF-κB from activators into transcriptional repressors (51) . Thus, HMG-like proteins can determine whether NF-κB functions as an activator or repressor of transcription, perhaps by local DNA (un)bending. A mammalian homologue of DSP-1 (as yet unidentified) may be involved in the down-regulation of E-selectin expression by binding at or close to the NF-κBII site. Distamycin may prolong E-selectin expression by inhibiting the binding of such a repressor.
An alternative, structure-based hypothesis may explain the effect of distamycin on E-selectin expression. HMG-I(Y) has been thought of as an architectural component of the NF-κB-promoter complex. The DNA binding domain of HMG-I(Y) has a predicted planar crescent shape, similar to distamycin (52) . Thus distamycin may replace HMG-I(Y) structurally and functionally in the site II complex when it is normally lost in down-regulation of the promoter, perhaps after phosphorylation. The continuous presence of distamycin would allow transcription; removal would stop transcription. These predictions are consistent with our observations that removal of distamycin results in rapid down-regulation of E-selectin expression. Our finding that other DNA binding compounds not well known to bend DNA did not affect E-selectin transcription (Fig. 4) suggests that distamycin's DNA bending capacity plays a role in this transcriptional on/off switch. It was recently found that distamycin also binds NF-κB elements in the HIV promoter (53) , but in this case transcriptional effects were not explored.
This study provides evidence for the importance of the NF-κBII site of the promoter in down-regulation of E-selectin expression and suggests HMG-I(Y) DNA bending as a modulator of NF-κΒ function. Identifying the components of the NF-κBII binding complex and how they change with time following cytokine induction of the promoter will be important. Clarifying the precise means by which the E-selectin promoter is downregulated will also add significant insight into the many other promoters whose regulation involves NF-κB-like complexes and why and how these evoke different transcriptional responses.
